These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 35247290)

  • 1. A Phase 1, Open-Label Study to Evaluate the Effect of Food and Concomitant Itraconazole Administration on the Pharmacokinetics of AMG 986 in Healthy Subjects.
    Trivedi A; Mather O; Vega S; Hutton S; Hellawell J; Lee E
    Clin Pharmacol Drug Dev; 2022 Jul; 11(7):849-856. PubMed ID: 35247290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects.
    Fukumura K; Kawaguchi N; Ishibashi T; Kubota R; Tada Y; Ogura E
    Clin Drug Investig; 2020 Jun; 40(6):529-540. PubMed ID: 32323104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic Drug Interactions of an Orally Available TRH Analog (Rovatirelin) With a CYP3A4/5 and P-Glycoprotein Inhibitor (Itraconazole).
    Kobayashi K; Abe Y; Kawai A; Furihata T; Endo T; Takeda H
    J Clin Pharmacol; 2020 Oct; 60(10):1314-1323. PubMed ID: 32459872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
    Li J; Rockich K; Yuska B; Zhou G; Epstein N; Punwani N; Chen X; Yeleswaram S
    J Clin Pharmacol; 2020 Nov; 60(11):1519-1526. PubMed ID: 32515832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of itraconazole and rifampicin on the single-dose pharmacokinetics of the nonsteroidal mineralocorticoid receptor blocker esaxerenone in healthy Japanese subjects.
    Kirigaya Y; Shiramoto M; Ishizuka T; Uchimaru H; Irie S; Kato M; Shimizu T; Nakatsu T; Nishikawa Y; Ishizuka H
    Br J Clin Pharmacol; 2020 Oct; 86(10):2070-2079. PubMed ID: 32250463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of itraconazole and fluconazole on the pharmacokinetics of valemetostat: An open-label, phase I study in healthy subjects.
    Tachibana M; Matsuki S; Maekawa Y; Kuroda K; Shimizu T; Tsutsumi J; Ishizuka H
    Clin Transl Sci; 2023 Nov; 16(11):2153-2162. PubMed ID: 37705321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor.
    Desch M; Wunderlich G; Goettel M; Goetz S; Liesenfeld KH; Chan TS; Rosenbrock H; Sennewald R; Link J; Keller S; Wind S
    Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):91-103. PubMed ID: 34716565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Strong Inhibition of Cytochrome P450 3A and UDP glucuronosyltransferase 1A9 and Strong Induction of Cytochrome P450 3A on the Pharmacokinetics, Safety, and Tolerability of Soticlestat: Two Drug-Drug Interaction Studies in Healthy Volunteers.
    Yin W; Dong C; Stevenson A; Lloyd V; Petrillo M; Baratta M; Hui T; Han S
    Drug Metab Dispos; 2024 Feb; 52(3):180-187. PubMed ID: 38123352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healthy Chinese subjects.
    Cao B; Huang L; Liu M; Lin H; Ma T; Zhao Y; Geng Y; Yang Y; Guo H; Li J
    Expert Opin Drug Metab Toxicol; 2023 Sep; 19(9):653-664. PubMed ID: 37811634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug-Drug Interaction Study.
    Poggesi I; Li LY; Jiao J; Hellemans P; Rasschaert F; de Zwart L; Snoeys J; De Meulder M; Mamidi RNVS; Ouellet D
    Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):101-111. PubMed ID: 31673875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of itraconazole and carbamazepine on the pharmacokinetics of nirmatrelvir/ritonavir in healthy adults.
    Cox DS; Van Eyck L; Pawlak S; Beckerman B; Linn C; Ginman K; Thay Cha Y; LaBadie RR; Shi H; Damle B
    Br J Clin Pharmacol; 2023 Sep; 89(9):2867-2876. PubMed ID: 37184075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study.
    Mu S; Lin C; Skrzypczyk-Ostaszewicz A; Bulat I; Maglakelidze M; Skarbova V; Andreu-Vieyra C; Sahasranaman S
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):81-88. PubMed ID: 33772633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Food and Omeprazole on a Novel Formulation of Super Bioavailability Itraconazole in Healthy Subjects.
    Lindsay J; Mudge S; Thompson GR
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30297369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the Pharmacokinetic Drug Interaction of Capmatinib With Itraconazole and Rifampicin and Potential Impact on Renal Transporters in Healthy Subjects.
    Cui X; Chen X; Pognan N; Sengupta T; Rahmanzadeh G; Kornberger R; Giovannini M
    J Clin Pharmacol; 2023 Feb; 63(2):228-238. PubMed ID: 36087217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
    Tugnait M; Gupta N; Hanley MJ; Sonnichsen D; Kerstein D; Dorer DJ; Venkatakrishnan K; Narasimhan N
    Clin Pharmacol Drug Dev; 2020 Feb; 9(2):214-223. PubMed ID: 31287236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes.
    Gardin A; Shakeri-Nejad K; Feller A; Huth F; Neelakantham S; Dumitras S
    Eur J Clin Pharmacol; 2019 Nov; 75(11):1565-1574. PubMed ID: 31392364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of CYP3A Inhibition, CYP3A Induction, and Gastric Acid Reduction on the Pharmacokinetics of Ripretinib, a Switch Control KIT Tyrosine Kinase Inhibitor.
    Li X; Shelton MJ; Wang J; Meade J; Ruiz-Soto R
    Clin Pharmacol Drug Dev; 2022 Oct; 11(10):1165-1176. PubMed ID: 35560823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AMG 986 in Healthy Japanese Subjects.
    Trivedi A; Mather O; Vega S; Hutton S; Hellawell J; Lee E
    Drugs R D; 2022 Jun; 22(2):141-146. PubMed ID: 35279815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of nirmatrelvir/ritonavir on midazolam and dabigatran pharmacokinetics in healthy participants.
    Cox DS; Rehman M; Khan T; Ginman K; Salageanu J; LaBadie RR; Wan K; Damle B
    Br J Clin Pharmacol; 2023 Nov; 89(11):3352-3363. PubMed ID: 37354048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the Pharmacokinetics and Safety of AMG 986 Tablet and Capsule Formulations in Healthy Adult Subjects: A Phase I, Open-Label, Randomized Study.
    Trivedi A; Kiang YH; Saw RE; Cheng GC; Mather O; Vega S; Hellawell J; Lee E
    Drugs R D; 2022 Jun; 22(2):147-154. PubMed ID: 35412220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.